{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:59Z","timestamp":1794047459881,"version":"4.8.0"},"reference-count":16,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.284694","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:28:06Z","timestamp":1708576086000},"page":"2337-2340","source":"Crossref","is-referenced-by-count":1,"title":["Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and\/or refractory multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Maria Victoria","family":"Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sossana","family":"Delimpasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Larocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Rodriguez","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"63783","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020). Ann Oncol. 2021; 32(3):309-322.","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"63784","doi-asserted-by":"crossref","unstructured":"Gandhi UH, Cornell RF, Lakshman A. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33(9):2266-2275.","DOI":"10.1038\/s41375-019-0435-7"},{"key":"63785","doi-asserted-by":"crossref","unstructured":"Lee L, Bounds D, Paterson J. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016; 174(6):911-922.","DOI":"10.1111\/bjh.14145"},{"key":"63786","doi-asserted-by":"crossref","unstructured":"O\u2019Connor BP, Raman VS, Erickson LD. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004; 199(1):91-98.","DOI":"10.1084\/jem.20031330"},{"key":"63787","doi-asserted-by":"crossref","unstructured":"Nath K, Costa BA, Mailankody S. GPRC5D as a novel immunotherapeutic target in multiple myeloma. Nat Rev Clin Oncol. 2023; 20(5):281-282.","DOI":"10.1038\/s41571-023-00735-4"},{"key":"63788","doi-asserted-by":"crossref","unstructured":"Montes de Oca R, Alavi AS, Vitali N. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immunemediated antitumor responses in vivo. Mol Cancer Ther. 2021; 20(10):1941-1955.","DOI":"10.1158\/1535-7163.MCT-21-0035"},{"key":"63789","doi-asserted-by":"crossref","unstructured":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015; 7(11):1187-1199.","DOI":"10.2217\/imt.15.77"},{"key":"63790","doi-asserted-by":"crossref","unstructured":"Tai YT, Mayes PA, Acharya C. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-3138.","DOI":"10.1182\/blood-2013-10-535088"},{"key":"63791","doi-asserted-by":"crossref","unstructured":"Nooka AK, Cohen AD, Lee HC. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer. 2023; 129(23):3746-3760.","DOI":"10.1002\/cncr.34987"},{"key":"63792","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023; 10(10):e801-e812.","DOI":"10.1016\/S2352-3026(23)00243-0"},{"key":"63793","unstructured":"Mateos M-V, Beksac M, Dimopoulos M. Results from the randomized, open-label phase 3 CANOVA study of venetoclax-dexamethasone versus pomalidomide- dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma. Presented at International Myeloma Society Annual Meeting; September 27-30, 2023; Athens, Greece."},{"key":"63794","unstructured":"Schjesvold FH, Dimopoulos MA, Delimpasi S. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022; 9(2):e98-e110."},{"key":"63795","doi-asserted-by":"crossref","unstructured":"Richardson PG, Oriol A, Larocca A. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021; 39(7):757-767.","DOI":"10.1200\/JCO.20.02259"},{"key":"63796","doi-asserted-by":"crossref","unstructured":"de la Rubia J, Alonso R, Clavero ME. Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: results of the compassionate use or the expanded access program in Spain. Cancers (Basel). 2023; 15(11):2964.","DOI":"10.3390\/cancers15112964"},{"key":"63797","doi-asserted-by":"crossref","unstructured":"Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D. Real-world effectiveness and safety of belantamab mafodotin monotherapy in triple-class refractory multiple myeloma. Int J Mol Sci. 2023; 24(14):11829.","DOI":"10.3390\/ijms241411829"},{"key":"63798","doi-asserted-by":"crossref","unstructured":"Markouli M, Ullah F, Unlu S. Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management. Curr Oncol. 2023; 30(7):6330-6352.","DOI":"10.3390\/curroncol30070467"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284694\/76632","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284694\/77225","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11470\/76632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:46Z","timestamp":1794045946000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284694","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}